Physician profile
Kenneth Chan
NPI 1720042138
$10,218.83
in general payments reported to CMS, 2019-2025
47 companies · $2,074 in 2025
The $2,074 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $583 · 2020: $216 · 2021: $1,460 · 2022: $1,780 · 2023: $1,904 · 2024: $2,202 · 2025: $2,074.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,030 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,029.87 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,677.25 | 2021-2025 | Botox, Ubrelvy, Qulipta |
| Novartis Pharmaceuticals Corporation | $1,452.01 | 2019-2025 | |
| Biogen, INC. | $1,003.37 | 2020-2025 | Vumerity, Tysabri, Spinraza |
| Ucb, INC. | $541.89 | 2020-2025 | Zilbrysq, Rystiggo, Briviact |
| Genzyme Corporation | $520.42 | 2019-2023 | |
| Alexion Pharmaceuticals, INC. | $514.37 | 2019-2024 | Ultomiris |
| Pfizer INC. | $467.87 | 2023-2025 | |
| Allergan, INC. | $374.24 | 2019-2022 | |
| Amgen INC. | $356.37 | 2020-2025 | Uplizna |
| Emd Serono, INC. | $258.72 | 2022-2025 | Mavenclad |
| Springworks Therapeutics, INC. | $235.55 | 2024-2025 | Gomekli |
| Mdd US Operations, LLC | $224.93 | 2023-2025 | Apokyn, Apokyn, Gocovri |
| Argenx US, INC. | $224.91 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Neurelis, INC. | $194.83 | 2021-2025 | Valtoco |
| Lundbeck LLC | $184.18 | 2022-2024 | Vyepti |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $180.16 | 2022-2024 | Emgality, Reyvow |
| Genentech USA, INC. | $168.08 | 2019-2025 | Ocrevus Zunovo, Ocrevus |
| Neurocrine Biosciences, INC. | $161.84 | 2022-2025 | Ingrezza, Ongentys |
| Otsuka America Pharmaceutical, INC. | $141.93 | 2023-2025 | Rexulti |
| Eisai INC. | $119.44 | 2021-2025 | |
| Amneal Pharmaceuticals LLC | $107.40 | 2023-2025 | Crexont, Rytary |
| Tg Therapeutics, INC. | $106.26 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $105.54 | 2022-2025 | Wainua |
| Janssen Pharmaceuticals, INC | $99.12 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $95.15 | 2021 | |
| Sumitomo Pharma America, INC. | $75.42 | 2023-2024 | Aptiom |
| Livanova USA, INC. | $61.63 | 2023-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Sunovion Pharmaceuticals INC. | $54.84 | 2021 | |
| Alnylam Pharmaceuticals INC. | $51.06 | 2022-2023 | Onpattro |
| Teva Pharmaceuticals USA, INC. | $39.87 | 2021-2024 | Austedo Xr |
| Tanabe Pharma America, INC. | $39.44 | 2020-2022 | |
| Kyowa Kirin, INC. | $39.24 | 2022-2024 | Nourianz |
| Banner Life Sciences, LLC | $36.59 | 2022-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $35.53 | 2022 | |
| Scilex Pharmaceuticals INC. | $35.18 | 2025 | |
| Celgene Corporation | $34.41 | 2024 | Zeposia |
| Acadia Pharmaceuticals INC | $32.84 | 2025 | Nuplazid |
| Supernus Pharmaceuticals, INC. | $26.98 | 2020 | |
| Merz Pharmaceuticals, LLC | $22.99 | 2025 | Xeomin, Ampyra, Inbrija |
| Medtronic, INC. | $21.06 | 2023 | Intellis Adaptivestim |
| Horizon Therapeutics Plc | $19.76 | 2022 | |
| Sk Life Science, INC. | $18.23 | 2022 | |
| Avion Pharmaceuticals | $16.30 | 2022 | |
| Nevro Corp. | $14.33 | 2022 | |
| Akcea Therapeutics, INC. | $14.08 | 2019 | |
| Currax Pharmaceuticals LLC | $13.22 | 2024 | Onzetra Xsail |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.